Health & Biotech
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Cann Group.
RELATED STOCKHEAD STORIES
Health & Biotech
Health Check: Despite headwinds, Australia’s third force in pharmacy finds prescription for growth
News
ASX Small Caps Lunch Wrap: Wall Street says ‘jump’, ASX says ‘how high?’
Health & Biotech
Health Check: Lion City’s Orthocell approval provides a Singapore Sling-board to Asian markets
Health & Biotech
September Health Winners: EZZ and Althea lead upbeat sector sparked by Fed rate cut
Health & Biotech
Health Check: Medical pot play Cann Group sees an earnings turnaround through the haze
Health & Biotech
Bio Curious: Nerve repair house plans to break the IPO drought
News
Things you may not know about Made in Australia, and ASX stocks that manufacture right here
Health & Biotech
Weed Week: Jamaican nettletree could be a new, cheaper option to source CBD, says scientists
Health & Biotech
Weed Week: Big win for cannabis as SAFER Banking Act approved; market remains robust in Australia
Health & Biotech
Weed Week: Short sellers burned as cannabis stocks stage a rebound. Where to next?
Health & Biotech
Weed Week: Mastercard says NO to cannabis transactions, as New York becomes the happening place for weed
Health & Biotech
ASX Health Stocks: Medibio jumps 50pc on Phase 1 results; Cann doubles cannabis harvest
Health & Biotech
ASX Health Stocks: Cann’s cannabis flower sales grow 500pc; Immuron runs out of Travelan as travel rebounds
News
Banking on pot: Minus one global investment house, Switzerland moves to legalise cannabis
Health & Biotech
Weed Week: BOD advances Aqua Phase acquisition with stability testing
Health & Biotech
ASX Health Stocks: Most biotechs are still chasing maiden revenue, but here’s a few healthcare stocks with strong earnings
Health & Biotech
